CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the stock.

CLGN has been the subject of a number of other reports. D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of CollPlant Biotechnologies in a research report on Wednesday, November 27th. EF Hutton Acquisition Co. I upgraded shares of CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th.

CollPlant Biotechnologies Trading Up 5.4 %

Shares of CollPlant Biotechnologies stock opened at $4.48 on Friday. CollPlant Biotechnologies has a 1 year low of $3.31 and a 1 year high of $6.99. The company has a market cap of $51.30 million, a P/E ratio of -2.91 and a beta of 0.44. The stock has a 50-day moving average price of $4.29 and a 200 day moving average price of $4.81.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CLGN. Benjamin Edwards Inc. acquired a new stake in shares of CollPlant Biotechnologies during the 3rd quarter valued at about $112,000. Pinnacle Associates Ltd. increased its holdings in CollPlant Biotechnologies by 6.4% in the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after buying an additional 33,905 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC raised its position in CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after acquiring an additional 95,000 shares in the last quarter. 21.69% of the stock is owned by institutional investors and hedge funds.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.